Peter Bartenstein
Peter Bartenstein is a nuclear medicine head whose department is a leading European PSMA theranostics centre.
Peter Bartenstein directs nuclear medicine at LMU Munich, a high-volume centre for PSMA PET and 177Lu-PSMA therapy that co-developed 177Lu-PSMA-I&T.
Pages like this
not linked directly; found by shared links- CompanyClarity Pharmaceuticals
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonJeremie Calais
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonThomas A. Hope
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonRahul Aggarwal
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- TrialECLIPSE
Shares 177Lu-PSMA-I&T, Prostate cancer.
- PersonJohannes Czernin
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- TrialSPLASH
Shares 177Lu-PSMA-I&T, Prostate cancer.
- ProductFlotufolastat F-18
Shares PSMA, PSMA PET, Prostate cancer.